Strategies for minimizing immunosuppression in kidney transplantation

被引:47
作者
Kirk, AD [1 ]
Mannon, RB [1 ]
Swanson, SJ [1 ]
Hale, DA [1 ]
机构
[1] NIDDKD, Transplantat Branch, Dept Hlth & Human Serv, NIH, Bethesda, MD 20892 USA
关键词
immunosuppression; tolerance; transplant;
D O I
10.1111/j.1432-2277.2004.00019.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Immunosuppression remains the cause of most morbidity following organ transplantation. However, its use is also responsible for the outstanding graft and patient survival rates commonplace in modern transplantation. Thus, the predominant challenge for transplant clinicians is to provide a level of immunosuppression that prevents graft rejection while preserving immunocompetence against environmental pathogens. This review will outline several strategies for minimizing or tailoring the use of immunosuppressive drugs. The arguments for various strategies will be based on clinical trial data rather than animal studies. A distinction will be made between conventional immunosuppressive drug reduction based on over-immunosuppression, and newer induction methods specifically designed to lessen the need for chronic immunosuppression. Based on the available data we suggest that most patients can be transplanted with less immunosuppression than is currently standard.
引用
收藏
页码:2 / 14
页数:13
相关论文
共 112 条
[1]   Hospitalizations for cytomegalovirus disease after renal transplantation in the United States [J].
Abbott, KC ;
Hypolite, IO ;
Viola, R ;
Poropatich, RK ;
Hshieh, P ;
Cruess, D ;
Hawkes, CA ;
Agodoa, LY .
ANNALS OF EPIDEMIOLOGY, 2002, 12 (06) :402-409
[2]   Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: A randomized, controlled study [J].
Abramowicz, D ;
Manas, D ;
Lao, M ;
Vanrenterghem, Y ;
del Castillo, D ;
Wijngaard, P ;
Fung, S .
TRANSPLANTATION, 2002, 74 (12) :1725-1734
[3]   Heterologous immunity: an overlooked barrier to tolerance [J].
Adams, AB ;
Pearson, TC ;
Larsen, CP .
IMMUNOLOGICAL REVIEWS, 2003, 196 (01) :147-160
[4]  
Agha IA, 2002, GRAFT, V5, pS65
[5]  
Ahsan N, 1999, TRANSPLANTATION, V68, P1865
[6]   Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus [J].
Artz, MA ;
Boots, JMM ;
Ligtenberg, G ;
Roodnat, JI ;
Christiaans, MHL ;
Vos, PF ;
Blom, HJ ;
Sweep, FCGJ ;
Demacker, PNM ;
Hilbrands, LB .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (07) :1880-1888
[7]   Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy [J].
Bakker, RC ;
Hollander, AAMJ ;
Mallat, MJK ;
Bruijn, JA ;
Paul, LC ;
de Fijter, JW .
KIDNEY INTERNATIONAL, 2003, 64 (03) :1027-1034
[8]   Innate immune responses to transplants: A significant variable with cadaver donors [J].
Baldwin, WM ;
Larsen, CP ;
Fairchild, RL .
IMMUNITY, 2001, 14 (04) :369-376
[9]  
Barber W H, 1990, Clin Transpl, P289
[10]   Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? [J].
Birkeland, SA ;
Hamilton-Dutoit, S .
TRANSPLANTATION, 2003, 76 (06) :984-988